地中海贫血管理最佳实践:印度血液学与输血学会推荐
该推荐由印度血液学与输血学会(ISHBT)通过结构化多学科共识流程和专家评审制定,旨在为印度不同医疗环境下的地中海贫血诊断、治疗、监测和预防提供全面的循证指导。指南涵盖输血依赖型地中海贫血(TDT)和非输血依赖型地中海贫血(NTDT)的临床谱系,强调通过血液学指标、血红蛋白组分分析和分子检测进行早期诊断。对合理输血实践、铁过载监测和及时启动铁螯合治疗以预防心脏、肝脏、内分泌和骨骼并发症给出了明确推荐。还概述了铁相关器官损伤、感染、内分泌功能障碍、生育问题、妊娠和急诊场景的疾病特异性管理,以及造血干细胞移植、基因治疗和luspatercept、羟基脲、沙利度胺等新药的治愈和疾病修饰选择。预防策略强调携带者筛查、产前和 prenatal 诊断、遗传咨询和公众意识倡议。
要点
- 推荐通过血液学指标、血红蛋白组分分析及必要时分子检测进行地中海贫血早期诊断,以区分TDT与NTDT。
- 对TDT患者推荐合理输血实践,并监测铁过载,及时启动铁螯合治疗以预防心脏、肝脏、内分泌和骨骼并发症。
- 疾病特异性管理涵盖铁相关器官损伤、感染、内分泌功能障碍、生育问题、妊娠及急诊场景。
- 治愈和疾病修饰选项包括造血干细胞移植、基因治疗及luspatercept、羟基脲、沙利度胺等新药。
- 预防策略强调携带者筛查、产前和 prenatal 诊断、遗传咨询及公众意识倡议。
适用人群与场景
- 输血依赖型地中海贫血(TDT)和非输血依赖型地中海贫血(NTDT)患者。
- 适用于印度不同医疗环境下的地中海贫血管理。
诊断标准与关键阈值
- 早期诊断通过血液学指标、血红蛋白组分分析及必要时分子检测。
处置流程与药物剂量
- 合理输血实践。
- 铁过载监测。
- 及时启动铁螯合治疗以预防心脏、肝脏、内分泌和骨骼并发症。
- 疾病特异性管理铁相关器官损伤、感染、内分泌功能障碍、生育问题、妊娠及急诊场景。
- 治愈和疾病修饰选项包括造血干细胞移植、基因治疗及luspatercept、羟基脲、沙利度胺等新药。
- 预防策略包括携带者筛查、产前和 prenatal 诊断、遗传咨询及公众意识倡议。
研究设计与关键结果
- 制定机构:印度血液学与输血学会(ISHBT)。
- 方法:结构化多学科共识流程和专家评审。
- 目标:提供全面的循证指导,统一全国最佳实践,同时允许区域适应性调整。
证据类型、等级与局限
- 证据类型:指南(专家共识)。
对床旁实践的改变
- 推荐通过血液学指标、血红蛋白组分分析及必要时分子检测进行早期诊断。
- 推荐合理输血实践、铁过载监测和及时启动铁螯合治疗以预防并发症。
- 推荐疾病特异性管理铁相关器官损伤、感染、内分泌功能障碍、生育问题、妊娠及急诊场景。
- 推荐考虑造血干细胞移植、基因治疗及luspatercept、羟基脲、沙利度胺等治愈和疾病修饰选项。
- 推荐携带者筛查、产前和 prenatal 诊断、遗传咨询及公众意识倡议作为预防策略。
指南或共识出处
- 指南名称:Best Practices for Thalassaemia Management: Recommendations by Indian Society of Haematology and Blood Transfusion。
- 发布机构:印度血液学与输血学会(ISHBT)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Thalassemia comprises a heterogeneous group of most common monogenetic disorder and inherited autosomal recessive hemoglobin disorders characterized by defective globin chain synthesis, resulting in hemolysis, ineffective erythropoiesis, chronic anemia, and multisystem complications. India bears a substantial thalassemia burden, with millions of carriers and over 12,000 affected births annually, necessitating standardized, context-appropriate management strategies. These recommendations by the Indian Society of Haematology and Blood Transfusion (ISHBT) provide comprehensive, evidence-informed guidance for the diagnosis, treatment, monitoring, and prevention of thalassemia across diverse healthcare settings in India. The recommendation developed through a structured, multidisciplinary consensus process and expert review, these guidelines aim to harmonize best practices nationwide while allowing flexibility for regional adaptation. Their implementation is expected to improve survival, quality of life, and long-term outcomes for individuals living with thalassemia in India. The guidelines address the clinical spectrum, including transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT), emphasizing early diagnosis through hematological indices, hemoglobin fraction analysis, and molecular testing when indicated. Clear recommendations are provided for rational blood transfusion practices, iron overload monitoring, and timely initiation of iron chelation therapy to prevent cardiac, hepatic, endocrine, and skeletal complications. Disease-specific management of iron-related organ damage, infections, endocrine dysfunction, fertility issues, pregnancy, and emergency scenarios is outlined. Curative and disease-modifying options including hematopoietic stem cell transplantation, gene therapy, and newer agents such as luspatercept, hydroxyurea, and thalidomide are outlined. Preventive strategies, highlighting carrier screening, antenatal and prenatal diagnosis, genetic counseling, and public awareness initiatives.
参考来源
- Dolai TK, Jena RK, Roy S, et al. Best Practices for Thalassaemia Management: Recommendations by Indian Society of Haematology and Blood Transfusion. Indian J Hematol Blood Transfus. 2026. PMID: 42040714. doi:10.1007/s12288-026-02390-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。